Orphanet Journal of Rare Diseases | Assessing Rare Disease Research Progress Using the Disease Readiness Level Framework

Recommend:

This study introduces a novel Disease Readiness Level (DRL) framework to evaluate the understanding and development progress of rare diseases, providing a scientific basis for resource allocation and setting research priorities.

 

Literature Overview

The article titled 'Assessing rare disease understanding: a novel disease readiness level framework', published in Orphanet Journal of Rare Diseases, reviews a new disease readiness level (DRL) assessment framework inspired by NASA's technology readiness level (TRL) system. It aims to measure research progress and therapeutic development for rare diseases (RD). The article highlights the challenges faced in drug development for rare diseases and proposes the DRL framework to evaluate the entire process from disease concept establishment to drug approval, offering a unified standard for researchers, governments, and patient organizations.

Background Information

Rare diseases (RD) refer to diseases with extremely low prevalence in the population. Over 7,000 rare diseases have been identified globally. Due to the limited number of patients, pharmaceutical companies invest less in these diseases, resulting in a lack of effective treatments. Although several countries have established orphan drug incentive policies, a unified standard to assess disease research progress and unmet medical needs (UMN) has not been developed. The current Technology Readiness Level (TRL) framework is used to evaluate the maturity of technologies, but its focus is on product development rather than the entire disease research process. This article proposes a DRL framework that extends the assessment to early stages such as disease concept establishment, mechanism research, and clinical guideline development. It validates the framework's feasibility through four rare disease case studies: muscular dystrophy, fibrodysplasia ossificans progressiva (FOP), thrombocytopenia with growth deficiency (TGD), and idiopathic peripheral pulmonary artery stenosis (PPAS). The study emphasizes the critical role of patient organizations in disease research and clinical trials, and suggests future work to adapt the DRL framework for non-drug therapies, common diseases, and multi-stakeholder involvement.

 

A tool to preliminarily predict potential phenotypes before designing gene knockout experiments.

Learn More

 

Research Methods and Experiments

The research team developed a 9-level Disease Readiness Level (DRL) framework based on NASA's Technology Readiness Level (TRL) system to assess the entire process of rare disease research, from basic discovery to therapeutic development. The DRL framework defines multiple stages, ranging from disease identification (DRL 1) to drug approval (DRL 9), including disease concept establishment, mechanism research, applied research, clinical guideline development, drug screening, preclinical and clinical trials. The applicability of the framework was validated through four rare disease case studies: muscular dystrophy, FOP, TGD, and PPAS.

Key Findings and Perspectives

• The DRL framework provides a systematic evaluation of rare diseases from discovery to therapeutic development, offering a basis for resource allocation and priority setting.
• The framework divides disease research into early stages (DRL 1-5) and later drug development stages (DRL 6-9), introducing clinical guideline development as an intermediate milestone.
• Among the four case studies, muscular dystrophy reached DRL 9b (disease-modifying therapy), FOP reached DRL 8 (drug screening stage), TGD was at DRL 5 (clinical guidelines available but no specific treatment), and PPAS was at DRL 2 (only disease concept established).
• Patient organizations play a crucial role across multiple DRL stages (e.g., DRL 2 and DRL 8), including establishing registries and supporting clinical trials.
• DRL can be used to compare research progress among different rare diseases, helping governments, pharmaceutical companies, and patient organizations develop more effective R&D strategies.

Research Implications and Future Directions

This study introduces a unified evaluation framework for rare disease research, aiding in identifying research gaps and optimizing resource allocation. Future work may expand the DRL framework to non-drug therapies and further validate its applicability across more diseases. Additionally, DRL can be integrated with tools like START to support multi-stakeholder collaboration and policy-making.

 

A practical tool for quickly mapping DNA or RNA sequences to the genome.

Learn More

 

Conclusion

This article constructs a DRL framework based on NASA's TRL system to systematically evaluate rare disease research from basic discovery to therapeutic development. Through four case studies, the framework's utility in assessing research progress and guiding resource allocation decisions was demonstrated. DRL not only measures the level of disease understanding but also reflects drug development progress, offering scientific support for patient organizations, pharmaceutical companies, and government funding agencies. Although current limitations exist in terms of language, data completeness, and coverage of non-drug therapies, the framework provides a new perspective for rare disease research. Future enhancements may integrate multidimensional metrics to further optimize its application scope and practicality.

 

Kazuki Kitahara and Shingo Kano. Assessing rare disease understanding: a novel disease readiness level framework. Orphanet Journal of Rare Diseases.